| Controlled release of 5-fluorouracil from microporous zeolites M Spanakis, N Bouropoulos, D Theodoropoulos, L Sygellou, S Ewart, ... Nanomedicine: Nanotechnology, Biology and Medicine 10 (1), 197-205, 2014 | 102 | 2014 |
| Potential drug–drug interactions in prescriptions dispensed in community pharmacies in Greece A Chatsisvili, I Sapounidis, G Pavlidou, E Zoumpouridou, VA Karakousis, ... Pharmacy world & science 32, 187-193, 2010 | 97 | 2010 |
| Simultaneous determination of the flavonoid aglycones diosmetin and hesperetin in human plasma and urine by a validated GC/MS method: in vivo metabolic … M Spanakis, S Kasmas, I Niopas Biomedical Chromatography 23 (2), 124-131, 2009 | 65 | 2009 |
| Development and validation of a high performance liquid chromatographic method for the determination of oxcarbazepine and its main metabolites in human plasma and cerebrospinal … V Kimiskidis, M Spanakis, I Niopas, D Kazis, C Gabrieli, FI Kanaze, ... Journal of pharmaceutical and biomedical analysis 43 (2), 763-768, 2007 | 47 | 2007 |
| Determination of atenolol in human plasma by HPLC with fluorescence detection: validation and application in a pharmacokinetic study M Spanakis, I Niopas Journal of chromatographic science 51 (2), 128-132, 2013 | 32 | 2013 |
| Pharmacokinetic Interaction between Losartan and Rhodiola rosea in Rabbits M Spanakis, IS Vizirianakis, G Batzias, I Niopas Pharmacology 91 (1-2), 112-116, 2013 | 32 | 2013 |
| PharmActa: Personalized pharmaceutical care eHealth platform for patients and pharmacists M Spanakis, S Sfakianakis, G Kallergis, EG Spanakis, V Sakkalis Journal of Biomedical Informatics 100, 103336, 2019 | 29 | 2019 |
| PharmActa: empowering patients to avoid clinical significant drug–herb interactions M Spanakis, S Sfakianakis, V Sakkalis, EG Spanakis Medicines 6 (1), 26, 2019 | 28 | 2019 |
| Nursing personnel in the era of personalized healthcare in clinical practice M Spanakis, AE Patelarou, E Patelarou Journal of personalized medicine 10 (3), 56, 2020 | 26 | 2020 |
| Designing a digital patient avatar in the context of the MyHealthAvatar project initiative E Maniadi, H Kondylakis, EG Spanakis, M Spanakis, M Tsiknakis, ... 13th IEEE international conference on BioInformatics and BioEngineering, 1-4, 2013 | 26 | 2013 |
| Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics IS Vizirianakis, GA Mystridis, K Avgoustakis, DG Fatouros, M Spanakis Oncology Reports 35 (4), 1891-1904, 2016 | 25 | 2016 |
| Bioactive self-assembling lipid-like peptides as permeation enhancers for oral drug delivery C Karavasili, M Spanakis, D Papagiannopoulou, IS Vizirianakis, ... Journal of Pharmaceutical Sciences 104 (7), 2304-2311, 2015 | 25 | 2015 |
| ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF I Triviai, S Zeschke, J Rentel, M Spanakis, T Scherer, R Gabdoulline, ... Leukemia 33 (1), 99-109, 2019 | 24 | 2019 |
| A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological … M Spanakis, IS Vizirianakis, I Mironidou-Tzouvelekib, Maria, Niopas Biomed. Chromatogr 23, 1131-1137, 2009 | 24 | 2009 |
| Secure access to patient's health records using SpeechXRays a mutli-channel biometrics platform for user authentication EG Spanakis, M Spanakis, A Karantanas, K Marias 2016 38th Annual International Conference of the IEEE Engineering in …, 2016 | 20 | 2016 |
| Prevalence and clinical significance of drug–drug and drug–dietary supplement interactions among patients admitted for cardiothoracic surgery in greece M Spanakis, M Melissourgaki, G Lazopoulos, AE Patelarou, E Patelarou Pharmaceutics 13 (2), 239, 2021 | 16 | 2021 |
| Clinical and pharmacogenomic assessment of herb-drug interactions to improve drug delivery and pharmacovigilance IS Vizirianakis, M Spanakis, A Termentzi, I Niopas, E Kokkalou Plants in traditional and modern medicine: chemistry and activity, 978-81, 2010 | 15 | 2010 |
| Drug interactions for patients with respiratory diseases receiving COVID-19 emerged treatments M Spanakis, A Patelarou, E Patelarou, N Tzanakis International Journal of Environmental Research and Public Health 18 (21), 11711, 2021 | 14 | 2021 |
| Chlorogenic acid attenuates doxorubicin-induced oxidative stress and markers of apoptosis in cardiomyocytes via Nrf2/HO-1 and dityrosine signaling B Cicek, A Hacimuftuoglu, Y Yeni, B Danisman, M Ozkaraca, B Mokhtare, ... Journal of Personalized Medicine 13 (4), 649, 2023 | 13 | 2023 |
| Impact of adverse drug reactions in patients with end stage renal disease in Greece M Spanakis, M Roubedaki, I Tzanakis, M Zografakis-Sfakianakis, ... International Journal of Environmental Research and Public Health 17 (23), 9101, 2020 | 13 | 2020 |
Ioannis NiopasProfessor of Clinical Pharmacy and Pharmacokinetics, School of Pharmacy, Aristotle University of ThessalonikiVerified email at pharm.auth.gr
